These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1834088)

  • 1. Neuroprotectant effects of LY274614, a structurally novel systemically active competitive NMDA receptor antagonist.
    Schoepp DD; Ornstein PL; Salhoff CR; Leander JD
    J Neural Transm Gen Sect; 1991; 85(2):131-43. PubMed ID: 1834088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-(Tetrazolylalkyl)piperidine-2-carboxylic acids. Potent and selective N-methyl-D-aspartic acid receptor antagonists with a short duration of action.
    Ornstein PL; Schoepp DD; Arnold MB; Leander JD; Lodge D; Paschal JW; Elzey T
    J Med Chem; 1991 Jan; 34(1):90-7. PubMed ID: 1825117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation.
    Foster AC; Gill R; Woodruff GN
    J Neurosci; 1988 Dec; 8(12):4745-54. PubMed ID: 2904493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of LY233053: a structurally novel tetrazole-substituted competitive N-methyl-D-aspartic acid antagonist with a short duration of action.
    Schoepp DD; Ornstein PL; Leander JD; Lodge D; Salhoff CR; Zeman S; Zimmerman DM
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1301-8. PubMed ID: 2148188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kynurenic acid analogues with improved affinity and selectivity for the glycine site on the N-methyl-D-aspartate receptor from rat brain.
    Foster AC; Kemp JA; Leeson PD; Grimwood S; Donald AE; Marshall GR; Priestley T; Smith JD; Carling RW
    Mol Pharmacol; 1992 May; 41(5):914-22. PubMed ID: 1375317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage.
    Benavides J; Fage D; Carter C; Scatton B
    Brain Res; 1987 Sep; 421(1-2):167-72. PubMed ID: 2891401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.
    Fuller RW; Hemrick-Luecke SK; Ornstein PL
    Neuropharmacology; 1992 Oct; 31(10):1027-32. PubMed ID: 1436384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D,L-(tetrazol-5-yl) glycine: a novel and highly potent NMDA receptor agonist.
    Schoepp DD; Smith CL; Lodge D; Millar JD; Leander JD; Sacaan AI; Lunn WH
    Eur J Pharmacol; 1991 Oct; 203(2):237-43. PubMed ID: 1686860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-methyl-D-aspartic acid (NMDA) and non-NMDA receptors regulating hippocampal norepinephrine release. I. Location on axon terminals and pharmacological characterization.
    Pittaluga A; Raiteri M
    J Pharmacol Exp Ther; 1992 Jan; 260(1):232-7. PubMed ID: 1370540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative analysis of the neuroprotective properties of competitive and uncompetitive N-methyl-D-aspartate receptor antagonists in vivo: implications for the process of excitotoxic degeneration and its therapy.
    Massieu L; Thedinga KH; McVey M; Fagg GE
    Neuroscience; 1993 Aug; 55(4):883-92. PubMed ID: 7694181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinoxaline derivatives: structure-activity relationships and physiological implications of inhibition of N-methyl-D-aspartate and non-N-methyl-D-aspartate receptor-mediated currents and synaptic potentials.
    Randle JC; Guet T; Bobichon C; Moreau C; Curutchet P; Lambolez B; de Carvalho LP; Cordi A; Lepagnol JM
    Mol Pharmacol; 1992 Feb; 41(2):337-45. PubMed ID: 1371583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease.
    Dure LS; Young AB; Penney JB
    Ann Neurol; 1991 Dec; 30(6):785-93. PubMed ID: 1665055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CGS-19755 and MK-801 selectively prevent rat striatal cholinergic and gabaergic neuronal degeneration induced by N-methyl-D-aspartate and ibotenate in vivo.
    Schoepp DD; Salhoff CR; Hillman CC; Ornstein PL
    J Neural Transm Gen Sect; 1989; 78(3):183-93. PubMed ID: 2553073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of competitive NMDA receptor antagonists on excitatory amino acid-evoked currents in mouse spinal cord neurones.
    D'Hooge R; Raes A; Van de Vijver G; Van Bogaert PP; De Deyn PP
    Fundam Clin Pharmacol; 1999; 13(1):67-74. PubMed ID: 10027090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotection.
    Krogsgaard-Larsen P; Ferkany JW; Nielsen EO; Madsen U; Ebert B; Johansen JS; Diemer NH; Bruhn T; Beattie DT; Curtis DR
    J Med Chem; 1991 Jan; 34(1):123-30. PubMed ID: 1825114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists.
    Honoré T; Davies SN; Drejer J; Fletcher EJ; Jacobsen P; Lodge D; Nielsen FE
    Science; 1988 Aug; 241(4866):701-3. PubMed ID: 2899909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in excitatory amino acid receptor binding in the intact and decorticated rat neostriatum following insulin-induced hypoglycemia.
    Westerberg E; Wieloch TW
    J Neurochem; 1989 May; 52(5):1340-7. PubMed ID: 2565371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity.
    Bigge CF; Malone TC; Boxer PA; Nelson CB; Ortwine DF; Schelkun RM; Retz DM; Lescosky LJ; Borosky SA; Vartanian MG
    J Med Chem; 1995 Sep; 38(19):3720-40. PubMed ID: 7562904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinpocetine preferentially antagonizes quisqualate/AMPA receptor responses: evidence from release and ligand binding studies.
    Kiss B; Cai NS; Erdö SL
    Eur J Pharmacol; 1991 Dec; 209(1-2):109-12. PubMed ID: 1687679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: assessment of opioid receptor changes.
    Tiseo PJ; Cheng J; Pasternak GW; Inturrisi CE
    J Pharmacol Exp Ther; 1994 Jan; 268(1):195-201. PubMed ID: 8301558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.